Prostate cancer is the most common nonskin malignancy among men in Europe, North America, and Australia and, after lung cancer, represents the second leading cause of cancer-related death in men in these regions.4 Data from the Surveillance, Epidemiology, and End Results (SEER) program of the National Cancer Institute, which covers approximately 26% of the US population, show the rising incidence of cancer of the prostate (Figure 1).
Jonathan E. Rosenberg, MD, discusses the FDA approval of perioperative durvalumab plus enfortumab vedotin and considerations for treatment selection in cisplatin-ineligible MIBC.
Jessica Feehan, NP-C, discusses the expanding role of APPs in urology, from clinical leadership and procedures to care coordination and treatment initiation.
Sam S. Chang, MD, MBA, discusses treatment selection after BCG failure, including bladder-sparing options, cystectomy considerations, and the need for sequencing data.